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Abstract
Aging is the largest risk factor for a variety of noncommunicable diseases. Model
organism studies have shown that genetic and chemical perturbations can extend
both lifespan and healthspan. Aging is a complex process, with parallel and interact-
ing mechanisms contributing to its aetiology, posing a challenge for the discovery of
new pharmacological candidates to ameliorate its effects. In this study, instead of a
target‐centric approach, we adopt a systems level drug repurposing methodology to
discover drugs that could combat aging in human brain. Using multiple gene expres-
sion data sets from brain tissue, taken from patients of different ages, we first iden-
tified the expression changes that characterize aging. Then, we compared these
changes in gene expression with drug‐perturbed expression profiles in the Connec-
tivity Map. We thus identified 24 drugs with significantly associated changes. Some
of these drugs may function as antiaging drugs by reversing the detrimental changes
that occur during aging, others by mimicking the cellular defence mechanisms. The
drugs that we identified included significant number of already identified pro-
longevity drugs, indicating that the method can discover de novo drugs that melio-
rate aging. The approach has the advantages that using data from human brain
aging data, it focuses on processes relevant in human aging and that it is unbiased,
making it possible to discover new targets for aging studies.
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1 | INTRODUCTION
Life expectancy has increased steadily in many countries worldwide.
As aging is the major risk factor for multiple pathologies, including
cardiovascular diseases, neurodegenerative disorders and cancer
(Niccoli & Partridge, 2012), finding interventions that can increase
health during aging is of importance. Lifespan of laboratory model
organisms can be greatly extended by genetic and environmental
interventions, which also improve health and function during aging
(Clancy et al., 2001; Lucanic, Lithgow, & Alavez, 2013; Xiao et al.,
2013). Many of these interventions target components of the nutri-
ent‐sensing network and decrease the activity of IGF/insulin and/or
TOR signalling (Fontana, Partridge, & Longo, 2010). Moreover, diet-
ary restriction (DR), decreased food intake without malnutrition, can
increase lifespan and further supports the importance of nutrient‐
sensing pathways in aging (Fontana & Partridge, 2015).
Pharmacological intervention can also extend animal lifespan.
The DrugAge database reports drug‐induced lifespan extensions up
to 1.5‐fold for Caenorhabditis elegans, 1.1‐fold for Drosophila
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melanogaster and 31% for Mus musculus (Barardo et al., 2017). Some
of these chemicals may mimic the effects of DR (Fontana et al.,
2010). For example, resveratrol, which induces a similar gene expres-
sion profile to dietary restriction (Pearson et al., 2008), can increase
lifespan of mice on a high‐calorie diet, although not in mice on a
standard diet (Strong et al., 2013). Rapamycin, directly targets the
mTORC1 complex, which plays a central role in nutrient‐sensing net-
work and has an important role in lifespan extension by DR (Mair &
Dillin, 2008). Rapamycin extends lifespan by affecting autophagy and
the activity of the S6 kinase in flies. However, it can further extend
the fly lifespan beyond the maximum achieved by DR, suggesting
that different mechanisms might be involved (Bjedov et al., 2010).
Nevertheless, the mechanisms of action for most of the drugs are
not well known.
Several studies have taken a bioinformatics approach to discover
drugs that could extend lifespan in model organisms. For instance,
the Connectivity Map (CMap), a database of drug‐induced gene
expression profiles, has been used to identify DR mimetics and
found 11 drugs that induced expression profiles significantly similar
to those induced by DR in rats and rhesus monkeys (Calvert et al.,
2016). Another study generated a combined score reflecting both
the aging relevance of drugs based on the GenAge database and GO
annotations as well as the likely efficacy of the drugs in model
organisms, using structural analyses and other criteria such as solu-
bility (Ziehm et al., 2017). A machine learning approach has been
used to identify prolongevity drugs based on the chemical descrip-
tors of the drugs in DrugAge database and GO annotations of their
targets (Barardo et al., 2017). Using DrugAge as a training set, the
results reflect the known pathways in aging, and thus identified anti-
cancer and antiinflammatory drugs, compounds related to mitochon-
drial process and gonadotropin‐releasing hormone antagonists.
Another study took a pharmacological network approach to charac-
terize antiaging drugs, first screening a large library of 1,280 com-
pounds for lifespan extension in C. elegans. The 60 hits from the
screen were used to construct a pharmacological network and clus-
tered in certain pharmacological classes, mainly related to oxidative
stress (Ye, Linton, Schork, Buck, & Petrascheck, 2014).
Whereas most studies have focussed on model organisms, one
study used the known prolongevity drugs from the Geroprotectors
database (Moskalev et al., 2015) and asked whether these could be
functional in humans (Aliper et al., 2016). Using young and old
human stem cell expression profiles, they calculate a geroprotective
score based on the GeroScope algorithm, which scores drugs based
on the drug targets and age‐associated expression changes in related
pathways (Zhavoronkov, Buzdin, Garazha, Borisov, & Moskalev,
2014). Testing the top hits in senescent human fibroblast cultures,
they suggest several geroprotectors for humans as well as showing
the potential in using human gene expression data for drug studies.
Although previous studies tried to discover drugs that can affect
aging, they all focus on genes or drugs related to lifespan regulation.
The role of these drugs in promoting healthy aging in humans is still
an open question. In this study, using gene expression data for
human brain aging, we aimed to discover not only new prolongevity
drugs but also those that can improve health during aging. Human
brain undergoes substantial structural changes with age, including
changes in brain weight, white and grey matter volumes. Accompa-
nied by the altered intercellular communication and synaptic loss,
these changes bring about cognitive decline, neurodegeneration and
memory loss (Salthouse, 2009). The biological processes showing a
change in expression include pathways related to synaptic and cogni-
tive functions as well as proteostasis (Lu et al., 2004), suggesting
gene expression changes in the aging brain could be used as a surro-
gate to find drugs to target detrimental effects.
Here, we extended the previous approaches to identification
of new antiaging drugs for humans, by focusing directly on human
aging data. We used a framework that does not require any prior
knowledge and is thus robust to biases in the literature and data-
bases on aging. Moreover, using human age‐series data, this
methodology has the potential to discover drugs affecting both
lifespan and healthspan. Through a meta‐analysis of multiple gene
expression data sets, we first compiled a robust signature that
characterizes aging in human brain. We then used drug‐induced
RNA expression profiles deposited in CMap (Lamb, 2006) to iden-
tify a list of potential drug candidates that could influence human
brain aging. We then assessed the performance of the method in
relation to previous knowledge and identified novel candidate
geroprotective drugs.
2 | RESULTS
2.1 | Analysis of age‐related changes in RNA
expression in human brains
We analysed data from seven, published, microarray‐based studies
of age‐related changes in RNA expression (Barnes et al., 2011; Ber-
chtold et al., 2008; Colantuoni et al., 2011; Kang et al., 2011; Lu
et al., 2004; Maycox et al., 2009; Somel et al., 2010, 2011 ). The
data came from 22 different brain regions, and the ages of the
donors ranged from 20 to 106 years (Figure 1a and Supporting
Information Figure S1a). The data for each brain region in each study
were analysed separately, resulting in 26 data sets.
To characterize the association between the gene expression and
age, we calculated the Spearman correlation between the expression
level and age, for each gene, in each data set separately. We first
calculated the number of significant changes (FDR‐corrected
p < 0.05) in each data set (Supporting Information Figure S2).
Whereas there were two data sets with a large number of significant
changes, most of the data sets did not show substantial significant
change. This can be explained by several factors, most importantly
(a) most of the data sets had a small sample size, providing insuffi-
cient power to detect changes in most of the cases; and (b) Spear-
man's correlation test calculates significant monotonic changes,
whereas it is likely that many of the changes are not exclusively
monotonic throughout aging. Thus, we applied another approach,
using the correlation coefficient to capture significant trends across
data sets, instead of within a data set (see Methods). Whereas the
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p‐value is affected by the number of the samples and the strength
of the monotonic relationship (Figure 1b), the sign of the correlation
coefficient can be used to capture consistent trends of up‐ or down-
regulation once coupled with an appropriate testing scheme. This
strategy requires the data sets to be concordant and reflect genuine
age‐related changes. We first investigated whether this assumption
was valid. To assess the concordance among data sets, we used
Spearman's correlation coefficients and calculated the correlation
between expression–age correlations between data sets (Figure 1c).
We observed a weak correlation with a median pairwise correlation
coefficient of 0.29. To calculate the significance of this correlation,
we developed a stringent permutation scheme specifically designed
to account for the dependence between genes as well as the data
sets (see Methods for detail). We concluded that a median correla-
tion coefficient of 0.09 would be expected by chance and that our
observation (median ρ = 0.29), is statistically significant (p < 0.001).
Based on these correlations, data sets clustered according to the
data source rather than to the brain region. This observation is in
line with the previous studies suggesting that aging‐related changes
are small and heterogeneous, making them difficult to detect (Somel,
Khaitovich, Bahn, Pääbo, & Lachmann, 2006). We therefore tested
for significant correlations across data sets from different studies.
When we excluded the correlation coefficients among the data sets
generated by the same studies, we still observed a significant corre-
lation coefficient of 0.22 (permutation test p < 0.001, ρ = −0.002
would be expected by chance), showing that we have significant cor-
relations among different data sources as well. Using these correla-
tions, we proceeded to compile the aging signatures, reflecting
consistent trends.
2.2 | Defining the aging signature
To construct a robust aging signature, we identified the age‐related
changes that were observed across all data sets, irrespective of the
effect size. We thus focussed on global age‐related changes in the
brain, rather than region‐specific changes, and the set of genes that
showed gene expression changes in the same direction across all
data sets (Figure 2a). This profile consisted of only 100 upregulated
and 117 downregulated genes (Supporting Information Table S2, Fig-
ures S3 and S4), “the aging signature”.
To establish the robustness of the aging signature, we calculated
the statistical significance of the number of consistent changes with
the same permutation scheme used to test the correlations among
data sets. This methodology randomizes the age of each individual,
making it possible to test the null hypothesis where there is no asso-
ciation between expression and age while retaining the dependence
between genes and data sets (see Methods for details). The number
of consistent expression changes across brain regions was significant
(p < 0.001; Figure S6a,b), establishing that the aging signature
indeed has biological meaning.
To further test the robustness of the aging signature, we used an
independent data set, consisting of gene expression in human brain
generated by the GTEx Consortium (Ardlie et al., 2015), consisting of
data from 99 individuals, 13 brain regions and ages between 20 and
79 (Supporting Information Figure S1a, and Table S1). These data
were generated using RNA‐seq, allowing us to assess the robustness
of the aging signature to different technology platforms. We used
pipeline previously applied to the microarray data to calculated age‐
related expression changes for each gene in each brain region
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separately. The pairwise correlations between the GTEx data sets
were higher than with the other data set, and they tended to cluster
together (Supporting Information Figure S5). We found 1,189 upreg-
ulated and 1,352 downregulated genes that showed the same direc-
tion of change across all GTEx brain regions (Supporting Information
Table S2), compared with only 100 and 117 in the microarray aging
signature. A likely explanation is that samples from different brain
regions from the same individuals were used in GTEx, whereas the
microarray aging signature combined seven independent studies and
different microarray platforms. The numbers of shared expression
changes based on permutations were 127 and 131.5, for down‐ and
upregulated genes, suggesting a higher false positive rate in the
GTEx data set. Nevertheless, the numbers of consistent up‐ and
downregulated genes in the GTEx data set were also significant
(p = 0.001; Supporting Information Figure S6c,d). The numbers of
common up‐ and downregulated genes across the GTEx and microar-
ray signatures were 50 and 48, respectively, both statistically signifi-
cant (binomial test p < 2.2e‐16 for both), demonstrating that the
aging signature was reproducible.
2.3 | Biological processes associated with the aging
signature
We next investigated the biological processes associated with the
microarray aging signature. Using the genes that were consistently
expressed in all data sources as background, we did Gene Ontology
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enrichment tests for consistently up‐ and downregulated genes, sep-
arately (Figure 3, Supporting Information Table S3 [upregulated],
Table S4 [downregulated]). Downregulated genes were enriched in
synaptic functions and biosynthetic processes (FDR‐corrected
p < 0.05), whereas differentiation and proliferation‐related categories
showed enrichment for the upregulated genes (FDR‐corrected
p < 0.05). These results are consistent with the findings of earlier
brain aging transcriptome studies (Lu et al., 2004; Naumova et al.,
2012; Xue et al., 2007). Oddly, ossification‐related biological pro-
cesses also showed significant enrichment for the upregulated genes.
However, except for one gene, these ossification‐related categories
shared all genes with the more generic development‐related cate-
gories. Thus, this result could be interpreted as a general upregula-
tion of the development‐related processes rather than ossification‐
related categories.
We repeated the enrichment analysis using the GTEx aging sig-
nature and found 194 and 256 GO BP categories as significantly
associated with down‐ and upregulated genes, respectively (Support-
ing Information Tables S7 and S8). As the number of genes in the
GTEx signature is higher, we had more power to detect smaller
changes and thus had a higher number of significant associations.
However, the effect sizes (odds ratios) for each GO BP category cal-
culated for microarray and the GTEx aging signature were correlated
(Figure S7). Correlations between the odds ratios calculated for all of
the GO categories calculated in both methods were 0.46 and 0.37,
for the enrichment in the down‐ and upregulated genes, respectively.
Correlations increase when we considered only the GO categories
that are significantly associated with at least one of the aging signa-
tures: 0.55 and 0.60, for the enrichment in the down‐ and upregu-
lated genes, respectively. This further shows that the aging
signatures are robust. The categories enriched in downregulated
genes included biological processes related to neuronal and synaptic
functions, autophagy, posttranslational modifications and translation
(see Supporting Information Table S7 for the full list). Processes
related to response pathways, immune response, macromolecule
organization and lipid metabolism showed enrichment in upregulated
genes (see Supporting Information Table S8 for the full list). Interest-
ingly, categories related to ossification were also among the GO cat-
egories significantly associated with upregulation, based on GTEx
data.
2.4 | Mapping the aging signature onto drug‐
perturbed expression profiles
The Connectivity Map is a database of drug‐perturbed gene expres-
sion profiles (Lamb, 2006). It consists of 6,100 gene expression pro-
files for 1,309 drug perturbation experiments performed on five
different cell lines. The CMap algorithm uses a modified Kol-
mogorov–Smirnov test statistic to calculate the similarity of a drug‐
perturbed expression profile to the gene expression profile used to
query the database. A positive similarity score means that the drug‐
perturbed expression profile is similar to the query, whereas a nega-
tive score indicates a negative correlation (Figure 2b). Based on the
random permutations, the statistical significance of the similarity
score for each drug is calculated. Thus, the p‐value shows the proba-
bility of finding the same association when a random signature is
supplied. We queried the CMap database and identified drugs that
showed significant associations in either direction with the aging sig-
natures. To determine the robustness of this procedure, we queried
the CMap data using the microarray aging signature, and the top
trans-synaptic signalling
trans-synaptic signalling
thioester biosynthetic process
cofactor biosynthetic process
coenzyme biosynthetic
process
thioester metabolic process(a) (b)
F IGURE 3 Gene Ontology Biological Process Categories significantly enriched in (a) down‐ and (b) upregulated genes in the microarray
aging signature. Red circles represent the genes, and diamonds show the significantly associated GO categories, where FDR adjusted p < 0.05.
The size of the diamonds represents the effect size (odds ratio)
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500 upregulated and 500 downregulated genes from the GTEx aging
signature (see Methods). The correlation was significant (r = 0.52,
p < 2.2e‐16; Supporting Information Figure S3a) showing that the
two aging signatures produce reproducible overlaps with the CMap
database. To test the reproducibility and not bias the results due to
the technology used to generate the data, we preferred not to
combine aging signatures but report the resulting drug hits from the
two signatures separately. Nevertheless, it is noteworthy that the
drug similarity scores, generated using the overlap between
signatures, show significant correlation with the lists generated using
both microarray and GTEx signatures (Supporting Information
Figure S12).
Querying the CMap database, we identified 13 drugs significantly
associated (FDR‐corrected p < 0.05) with the microarray aging signa-
ture (Table 1 and Figure 4). Four of these drugs were previously
shown to extend lifespan in worms or flies in at least one experi-
ment (Supporting Information Table S9). The number of prolongevity
drugs rediscovered using this methodology was statistically signifi-
cant (p = 0.004), and only one drug would be expected based on
10,000 random permutations of drugs. Repeating the same analysis
with the GTEx aging signature, we identified 18 drugs, seven of
which were in common with the microarray results, including the
four known prolongevity drugs. In total, 24 drugs were significantly
associated with at least one of the aging signatures. The correlation
between the drug similarity scores for these 24 drugs calculated
based on the microarray and GTEx data was 0.88 (p < 9.44e‐09;
Supporting Information Figure S3b), indicating high concordance. As
the similarity scores show high correlation, the rest of the results will
be presented for the 24 drugs that are associated with at least one
of the aging signatures.
Overall, the method rediscovered seven known prolongevity
drugs in DrugAge database (p = 0.00023, based on 100,000 random
permutations): resveratrol, LY‐294002, wortmannin, sirolimus (also
known as rapamycin), trichostatin A, levothyroxine sodium and gel-
danamycin (Supporting Information Table S9).
2.5 | Targets of the drugs
Next, we investigated the targets of these 24 drugs, using the
ChEMBL, PubChem and DrugBank databases as well as through
manual curation of the literature (Table 1), and whether these targets
were previously implicated in aging, using GenAge human and model
organism databases (Figure 5). Except for four (rifabutin, securinine,
thioridazine, trifluoperazine); all drugs or their target genes had been
previously implicated in aging. Moreover, the drug–target association
network showed several clusters with multiple drugs sharing the
same targets: (a) Quinostatin was in the same cluster with two
known prolongevity drugs, wortmannin and LY‐294002, targeting
PI3 K subunits; (b) tanespimycin and alvespimycin shared the same
target with another DrugAge drug, geldanamycin, targeting HSP90;
(c) vorinostat shared one of its targets, HDAC6, with trichostatin A,
another DrugAge drug; (d) thioridazine and trifluoperazine had dopa-
mine and serotonin receptors as targets; and (e) irinotecan and
camptothecin shared TOP1 as their target. The fact that drugs tar-
geting the same proteins/acting through the same mechanism had
similar CMap similarity scores (Figure 4) further shows that our
results are biologically relevant and reflects potential mechanisms to
target aging.
TABLE 1 The drugs that are significantly associated (FDR‐
corrected p < 0.05) with at least one of the aging signatures
Drug name
Array
score
GTEx
score Target or mechanism of action
Securinine −0.65* −0.50* GABRA1‐5, GABRB1‐3
Levothyroxine
sodium
−0.41 −0.47* THRA, THRB
Cinchonine −0.2 −0.65* CYP2D6
Geldanamycin −0.45* −0.38* HSP90AA1
15‐delta
prostaglandin
J2
−0.38* −0.42* PPARG
Rifabutin −0.16 −0.6* BCL6
Atropine oxide −0.35* −0.17 –
Tanespimycin −0.18 −0.31* HSP90AA1
Alvespimycin −0.08 −0.33* HSP90AA1
Vorinostat 0.02 −0.41* HDAC1, HDAC2, HDAC3,
HDAC6
Trichostatin A 0.09 −0.3* HDAC6, HDAC7, HDAC8
Trifluoperazine 0.32* 0.13 DRD2, DRD3, DRD4, HTR2A,
HTR2C
Tretinoin 0.42* 0.12 RARA, RARB, RARC
LY‐294002 0.38* 0.21* PI3KCG
Thioridazine 0.35* 0.25 DRD2, DRD3, DRD4, HTR2A,
HTR2C
Sirolimus 0.28* 0.33* mTOR
Wortmannin 0.29* 0.42* PI3KR1, PI3KCA, PI3KCG
Resveratrol 0.42 0.48* SULT1B1, YARS, LTA4H, TTR,
NQO2, PTGS2, PTGS1, MAT2B,
CSNK2A1, CYP3A4, ESR1,
PPARG, SIRT1, SIRT5, CYP1A2,
CYP1A1, CYP1B1, NCOA2,
TNNC1
Emetine 0.52* 0.41 Protein synthesis inhibition
Daunorubicin 0.43 0.52* TOP2A, TOP2B
GW‐8510 0.47 0.55* CDK2, CDK5
Irinotecan 0.39 0.78* TOP1
Camptothecin 0.63* 0.56 TOP1
Quinostatin 0.86* 0.76* PI3KCA
Notes. Drug names in bold shows the drugs in DrugAge database.
“Score” is the mean similarity score given in the CMap output, based on
KS test.
*The similarity scores denoted with asterisk show the significant associa-
tions. The list is ordered by the mean of the similarity scores from nega-
tive to positive. Target or mechanism of action is manually curated from
literature (the relevant literature is given in the Supporting Information)
or extracted from CHEMBL, DrugBank and PubChem databases. The tar-
gets written in bold are found in the GenAge model organism or GenAge
human databases.
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2.6 | Drugs can act both by reversing aging effects
and mimicking responses
The general expectation from an “omics”‐based drug repurposing
study is the identification of drugs that can reverse the abnormalities
detected in the disease state, that is, identification of drugs with
negative similarity scores (Duran‐Frigola, Mateo, & Aloy, 2017). Fol-
lowing the same logic, one might expect drugs with antiaging poten-
tial to have negative scores. Interestingly, some of the known
prolongevity drugs had positive similarity scores to the aging signa-
tures, meaning that the drug‐induced profile was similar to the aging
signature. A plausible explanation for this observation is that aging
signatures may partly reflect cellular defence responses, helping to
alleviate the damaging effects of aging.
2.7 | Characterizing the biological functions
associated with prolongevity drugs
To identify the biological processes associated with the changes that
were reversed or mimicked by the prolongevity drugs, we used the
drugs documented in DrugAge that were rediscovered in our analy-
sis. We grouped the microarray aging signature into five categories,
based on the expression changes in aging (up or down), and the pro-
longevity drug‐induced profile (up, down or inconsistent; Supporting
Information Table S5). To compile the prolongevity drug profile, for
each probe‐set in the microarray aging signature, we asked whether
the seven DrugAge drugs induced similar changes. If the same direc-
tion of change was induced by more than half of these DrugAge
drugs, then we included these changes in the prolongevity drug pro-
file (see Methods for the details). We then analysed the biological
processes associated with the genes in these categories. The number
of genes is small, with no significant changes after multiple test cor-
rection. We therefore report the associations based on the highest
odds ratios only. For genes downregulated in aging, the changes
mimicked by the drugs were associated with autophagy and meta-
bolic processes (Supporting Information Table S6), whereas for
upregulated genes, prolongevity drugs tended to mimic the changes
in protein complex/cellular complex assembly‐related functions and
to reverse the changes observed in protein localization and immune‐
related functions (Supporting Information Table S6). These findings
are consistent with the mechanism of action for the most well‐
known prolongevity drugs. For example, sirolimus (rapamycin) is an
immunosuppressant approved for human use, and similar drugs can
enhance the response of elderly humans to immunization against
influenza (Mannick et al., 2014).
2.8 | Similarity among significant drugs based on
the expression changes at the functional level
To analyse the similarities among drugs based on expression level
changes, we performed a gene‐set enrichment analysis (GSEA) for
the drug‐induced expression profiles, including all genes irrespective
of whether a given gene is in the aging signature (see Methods). To
measure the similarity between drugs, we calculate the Spearman
rank correlation coefficients between the enrichment scores and
then cluster drugs based on these correlation coefficients. Notably,
drugs targeting the same proteins or pathways, for example, PI3 K
inhibitors LY294002, wortmannin and quinostatin, clustered
together. Using this functional level approach, we grouped drugs into
four groups: (a) known prolongevity drugs; (b) drugs clustering
together with at least one prolongevity drug; (c) drugs which clus-
tered together but did not cluster with any known prolongevity
drugs; and (d) drugs which did not cluster with any other drugs (Sup-
porting Information Figure S10).
2.9 | Aging signature in other tissues
As our analysis is based on an aging signature compiled using only
the brain tissue, we also explored whether this signature is represen-
tative of the other tissues. A plausible way to approach this question
is repeating the same analysis using other tissues. However, it is not
straightforward because (a) the number of data sets available for the
other tissues limits the capacity of our approach to compile
atropine oxide
securinine
geldanamycin
levothyroxine sodium
cinchonine
rifabutin
tanespimycin
vespimycin
trichostatin A
vorinostat
sirolimus
wortmannin
L
thioridazine
tretinoin
tr razine
quinostatin
irinotecan
camptothecin
emetine
resveratrol
daunorubicin
Array GTEx
F IGURE 4 Similarity score table for the drugs having at least
one significant association with the aging signatures. Each row
corresponds to a drug and columns correspond to two independent
aging signatures—using the microarray and the GTEx data sets. The
size of score labels indicates the significance of the results (FDR‐
corrected p < 0.05). The row labels written in bold indicates the
drugs in the DrugAge database
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consistent signatures, increasing false positives; and (b) we find that
the aging‐related changes in other tissues are not as consistent as in
brain (Supporting Information Figure S11a). Thus, we choose another
approach and asked whether the direction of change for the aging
signature we compiled is similar to the direction of change in other
tissues (Supporting Information Figure S11c). We also tested the sig-
nificance of the similarity in the direction of change based on ran-
dom permutations. As expected, GTEx brain data showed the
highest per cent similarity to the array signature. Eight of 35 data
sets showed more dissimilarity for the downregulated genes (i.e., per
cent similarity was lower than 50%), whereas only two were statisti-
cally significant, namely, liver and atrial appendage. Similarly, only 6/
35 data sets showed more dissimilarity for the upregulated genes,
whereas none was significant. We repeated the analysis with the
GTEx signature and observed similar results with only exception that
there were five data sets with significant dissimilarity for the down-
regulated genes (Supporting Information Figure S11e). Thus, it is
possible that brain signature includes some brain‐specific changes
but based on significant similarity, we can say it is also representa-
tive of other tissues.
3 | DISCUSSION
In this study, using gene expression data, we identified a set of drugs
that are likely to modulate aging in the human brain. Using a meta‐
analysis approach, we generated a reproducible aging signature that
represents multiple brain regions and is independent of the platform
used for the detection of expression. Using CMap, we identified
drugs highly associated with this aging signature. Based on the Dru-
gAge database, seven of these drugs were previously tested on
model organisms and prolonged lifespan in at least one experiment.
The fact that we successfully rediscovered a statistically significant
number of known lifespan modulators, without using any prior drug
aging information, suggests that the other drugs that we identified
also have a high potential to be modulators of the aging process/
lifespan. Eleven of these had targets implicated in aging, based on
GenAge database (Tacutu et al., 2018). These targets include exten-
sively studied aging‐modulators such as PI3 K subunits and histone
deacetylases. We also identified a group of novel candidates that are
not in aging databases, which can offer new targets and mechanisms
to modulate aging. These include drugs targeting serine/threonine,
v m
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Y
F IGURE 5 Schematic representation of the drug–target associations as a network. Blue and red nodes show drugs and targets,
respectively. The drugs with a light blue background are present in DrugAge database and the targets with a pink background are in either
GenAge model organism or GenAge human databases
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muscarinic acid, and GABA(A) receptors, protein translation and
BCL6 gene. Moreover, as we used human expression data, the drugs
we identified may affect not only lifespan but also the healthspan by
improving the cognitive functions. Indeed, some of the drugs or their
targets, for example, tretinoin targeting RAR genes and GW‐8510
targeting CDK2 and CDK5, were previously linked to neuroprotec-
tive functions or neurodegenerative diseases. A literature research
presented in Supporting Information provides more information on
the potential mechanisms of these top drugs and their potential
effect on both lifespan and healthspan in humans.
“Omics”‐based drug repurposing studies, such as the CMap, aim
to identify drugs reversing the profile induced by a biological state
of interest. Aging is a time‐dependent, complex phenomenon, which
induces subtler changes compared to development (Dönertaş et al.,
2017), or to a disease state such as Alzheimer's (Avramopoulos, Szy-
manski, Wang, & Bassett, 2011). The “omics” profile reflects two
potentially distinct contributions: the detrimental effects which occur
with age (e.g., accumulation of mutations) and the potentially benefi-
cial responses to those changes (e.g., the immune response). As a
result, CMap similarity score is not conclusive on its own. To charac-
terize the potential effects of drugs on aging (anti‐ or proaging
drugs), we use three different approaches: (a) comparison of the
drug‐induced expression profiles with the known prolongevity drug
profile (Supporting Information Figure S9); (b) functional analysis of
the drug‐induced gene expression changes (Supporting Information
Figure S10); and (c) compilation of literature on the drugs and tar-
gets (Supporting Information). On the basis of these analyses we
suggest that eight of seventeen drugs (quinostatin, trifluoperazine,
thioridazine, vorinostat, alvespimycin, tanespimycin, rifabutin and 15‐
d prostaglandin J2), which are not in DrugAge, are likely to have
positive effects, whereas topoisomerase inhibitors (camptothecin,
irinotecan and daunorubicin) can be detrimental and could act as
proaging drugs. Four of the remaining drugs, which are cinchonine,
securinine, emetine and tretinoin, do not cluster closely with any
known prolongevity drugs in Supporting Information Figure S10. Lit-
erature, however, suggests cinchonine and securinine are likely to
have negative effects (see Supporting Information), whereas emetine
and tretinoin could act as antiaging drugs. GW‐8510 and atropine
oxide could not be classified because neither the clustering results
nor literature evidence are conclusive.
It is important to note that none of the cell lines used to generate
the CMap data originates from the brain. The assumption for using
the CMap algorithm is that the effect we see in diverse cell lines
reflects the global profile of the drug perturbation and thus should be
also transferable to the brain. However, it is possible that drugs have
cell or tissue‐specific effects. Even if the drugs induce the same
expression changes in brain cells, an important question is: Can they
cross the blood–brain barrier to target the brain? If some of these
drugs have side effects on the CNS, it might be an indication that
these drugs can affect the brain and can be repurposed to target brain
aging. Only eight of the 24 compounds have reported side effects,
and all of them have at least one reported effect on the nervous sys-
tem, based on MedDRA system organ classes (Supporting Information
Table S10). This implies that these drugs can affect CNS, although we
do not have information on their ability to cross the barrier. The rest
may or may not cross the barrier to influence the expression in the
brain, but they may also improve health by targeting generic changes
throughout the body. The aging signatures from brain tissue show a
modest but significant similarity to expression profiles from nonbrain
tissues (Supporting Information Figure S10). Thus, it is possible that
we identified not only drugs specifically targeting aging in the brain
but also drugs targeting aging in other tissues. It is also possible that
there are drugs which can target brain aging with more potency, but
we cannot identify them because we do not have drug‐induced
expression profiles for brain cells. Another important technical draw-
back is that the data we used to generate the aging signature are bulk
RNA expression data sets, where the expression profile is an average
of all the cell types in the human brain. Focusing on the changes that
are observed ubiquitously across all brain regions, we aimed to focus
on global changes which are unlikely to be driven by cell type differ-
ences. However, future data sets generated using single‐cell expres-
sion profiling can greatly improve the understanding of both the aging
process itself and how the interventions work.
To summarize, this study provides an unbiased identification of
drugs that can target human brain aging. We first compiled a set of
gene expression changes that can characterize human brain aging and
asked whether there are drugs which alter the expression of the same
genes. We identified 24 drugs, seven of which were among known
prolongevity drugs. Our analysis suggests that antiaging drugs may
act by mimicking the response, whereas it is also possible that they
can reverse the detrimental changes in aging. On the basis of the lit-
erature research, we concluded that some of the drugs we identified
can directly modulate the lifespan, whereas some are more likely to
function by improving the cognitive functions and promoting the
healthy aging. We are in the process of experimentally testing a group
of the drugs that we have identified. We hope the information pre-
sented in this study will guide research community to further test and
identify chemical modulators of the aging process in humans.
4 | METHODS
4.1 | Data sets
To define the gene expression changes during aging, we only
included data sets with samples across different ages. In this way,
we calculated the changes that occur monotonically throughout the
aging process, rather than looking at differences in the young and
old group. Data sets used in this study are all published data sets
and include both microarray and RNA‐seq data. The preprocessing
steps for each are described below.
4.1.1 | Microarray data sets
We used seven microarray‐based RNA expression studies with sam-
ples from 22 brain regions that are not mutually exclusive (Supporting
Information Table S1). Data from different brain regions are processed
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and analysed separately, resulting in 26 data sets. The number of indi-
viduals in each data set ranges between 11 and 148. The total number
of individuals is 304, and the total number of samples is 805 (after
removing the outliers). Some studies include samples covering the
whole lifespan. However, in this study, we only considered samples
above 20 years of age, which corresponds to the age at first repro-
duction in human societies (Walker et al., 2006). Previous human brain
aging studies using transcriptome data have also suggested gene
expression patterns before and after the age of 20 are discontinuous
(Colantuoni et al., 2011; Dönertaş et al., 2017). As we are interested
in finding consistent tendencies in terms of the direction of change,
which can characterize aging, we only included samples above
20 years of age. As a result, the samples included in the analysis had
ages between 20 and 106. The microarray data were downloaded
from NCBI GEO (Barrett et al., 2013) using the accession numbers in
Supporting Information Table S1. Using “affy” (Gautier, Cope, Bolstad,
& Irizarry, 2004) or “oligo” (Carvalho & Irizarry, 2010) libraries in R,
RMA background correction is applied to the expression data. The
data are then log2‐transformed and quantile‐normalized (using “pre-
processCore” library in R). By visual inspection of the first and second
principal components of the probe‐set expression levels, outliers were
excluded from the further analysis (Supporting Information Table S1).
The age distributions for the data sets after outlier removal are given
in Supporting Information Figure S1a. Gene annotations for the
probe‐sets are obtained from the Ensembl database using the “bio-
maRt” library (Durinck, Spellman, Birney, & Huber, 2009) in R. Because
the annotations for the probe‐sets used in Kang et al. (2011) and
Colantuoni et al. (2011) are not available in Ensembl, we used the GPL
files deposited in GEO. If Ensembl gene IDs are not provided in the
GPL files, Entrez gene IDs were extracted and converted to Ensembl
Gene IDs using the “biomaRt” package. Probe‐set‐level expression
information is then mapped to gene IDs. In order not to duplicate
expression values, we excluded the probe‐sets corresponding to mul-
tiple genes. Expression values for the genes with multiple probe‐sets
were summarized using the mean expression levels. The PCA plots for
the samples using gene expression levels are given in Figure S1b.
4.1.2 | RNA‐seq data set
We analysed transcriptome data generated by GTEx project (v6p)
(Ardlie et al., 2015). Samples are filtered based on the cause of
death circumstances (4‐point Hardy Scale). Only the cases with a
death circumstanceof 1 (violent and fast deaths due to an accident)
and 2 (fast death of natural causes) are used for the downstream
analysis and the samples with illnesses are excluded. Among all tis-
sues, only the ones having at least 20 samples are considered. We
also excluded “Cells—Transformed Fibroblasts” category to include
only the samples from tissues. As a result, 35 data sets (17 major
tissue type) are used for the downstream analysis, 13 of which
were from the brain. The final set that we analysed includes 2,152
(623 for the brain) samples from 120 (99 for the brain) individuals.
The genes with median RPKM value of 0 are also excluded from
data. The RPKM values provided in the GTEx database are log2‐
transformed and quantile‐normalized for the downstream analysis.
Similar to the microarray data, we excluded the outliers based on
the visual inspection of the first and second principal components
(Supporting Information Table S1). Distribution of the ages and the
PCA plots after outlier exclusion are given in Supporting Informa-
tion Figure S1.
4.1.3 | Batch correction
In this study, each data set is analysed separately, and only the gene
expression changes that are consistent across all data sets are con-
sidered for the downstream analysis. As multiple data sets are not
combined, and data sets generated at different laboratories using dif-
ferent platforms unlikely to have the same confounders, we did not
apply a correction method other than quantile normalization and
outlier removal based on the PCA (using probe‐set‐level expression
data for microarrays and gene‐level expression data for RNA‐seq as
described above). Moreover, most of the data sets have a homoge-
nous sample set as the number of samples is low and for the data
sets with a large number of samples, we do not detect any cluster-
ing.
4.2 | Age‐related expression changes and the aging
signature
The Spearman rank correlation coefficients between age and gene
expression levels are used to measure age‐related expression
changes. Instead of combining the data sets, we calculated the
Spearman correlation for each gene, for each data set separately. As
a result, each gene had two measures to assess its age‐related
expression: (a) a correlation coefficient (ρ), indicating the strength
and the direction of change with age; and (b) a p‐value, showing the
significance of the association. The p‐values are corrected for multi-
ple testing using p.adjust function in R, with method = “FDR” argu-
ment. As the power to detect significant changes in each data set is
different and the sample size is small for most of the data sets, for
the downstream analysis we only used the correlation coefficients
(ρ) and assessed the significant gene expression change tendencies
that are consistent in all data sets. When a gene is upregulated by
age throughout the lifespan, then it would have a positive Spear-
man's correlation coefficient that is close to one. In contrast, a gene
would have negative correlation coefficient if it is downregulated.
When the association is not strong, the magnitude of the correlation
coefficient decreases, but the sign still reflects the direction of
change that is observed in most of the time points. We used the
sign of correlation coefficient, that is, the direction of change, to
compile the set of genes that show consistent changes across all
data sets. This set of genes is referred to as the “aging signature.”
The aging signature, thus, does not reflect the dramatic changes in
gene expression but captures consistent trends that are observed
across all data sets. The statistical significance of the aging signature
is calculated using a permutation scheme, testing the significance of
the consistency.
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4.3 | Permutation test
We used a permutation scheme that we developed earlier (Dönertaş
et al., 2017), to simulate the null hypothesis that there is no associa-
tion between age and the gene expression, while retaining the depen-
dence between genes and the data sets. Particularly, the ages of
individuals in each study are permuted (randomized) 1,000 times, and
if that individual donated multiple samples for different brain regions,
each sample is annotated with the same age. Then, the Spearman cor-
relation coefficient between these randomized ages and the gene
expression value for all genes are calculated. In this way, we retain the
dependence between genes (e.g., those regulated by the same tran-
scription factor) and the samples (e.g., donated by the same individu-
als). Permutations are performed using “sample” function in base R.
Using the correlation coefficients calculated through permuta-
tions performed as explained above, we tested (a) significance of the
correlations among data sets; (b) significance of the finding the same
or a higher number of consistently up‐ or downregulated genes, that
is, the aging signature. To test the significance of the correlations
among data sets, we calculated the correlations between the expres-
sion–age correlation coefficients calculated using the permutations.
We constructed the distribution for the median correlation coeffi-
cient among data sets (distribution of the 1,000 values) and calcu-
lated how many times the randomized values have higher correlation
than the value we calculate using the real ages. In this way, we cal-
culate an empirical p‐value. The median of the permuted values
reflects the value that would be expected by chance. Similarly, to
test the significance of the aging signature, we compiled permuted
aging signatures, for 1,000 times, and asked how many times we
have the same or higher value than the calculated number of genes
in the microarray or GTEx aging signatures. In this way, we calculate
the empirical p‐value and median of the number of shared tenden-
cies based on permutations, reflecting what would be expected by
chance.
4.4 | Gene ontology enrichment
Using “topGO” and “org.Hs.eg.db” libraries in R, we performed a
functional analysis of the aging signature. Using GO categories with
more than 10 annotated genes, we applied an enrichment test for
the Gene Ontology (GO; Ashburner et al., 2000) Biological Process
(BP) categories.
4.5 | Connectivity map analysis
A list of genes showing a consistent change in aging (the aging signa-
ture) is used to query CMap (Lamb, 2006). As CMap input requires
probe‐set ids, the “biomaRt” package in R is used to convert the gene
list to the probe‐set ids that are compatible with the CMap data. The
probe‐sets that are in both up‐ and downregulated probe‐set lists are
excluded from both lists. The final lists are used to query CMap data-
base to associate the aging signature with the drug‐perturbed expres-
sion profiles in the database. The resulting p‐values are FDR‐corrected
to account for multiple testing and adjusted p < 0.05 is used as the
significance threshold.
The aging signature compiled using the GTEx data had more
than 500 probe‐sets in both up and down lists. As the algorithm
requires an input with <500 entries, we used the ones with the
higher magnitude of expression change (median Spearman's rank
correlation coefficients across 13 brain regions). To show that this
does not bias the results, we repeated this step for 1,000 times
by randomly selecting 500 of the probe‐sets in the GTEx aging
signature. To automatize this process, we reimplemented CMap
algorithm in R and calculated the drug similarity scores using the
“rankMatrix.txt” data provided on the CMap website. Drug similar-
ity scores generated using the top 500 and randomly selected
500 of the GTEx aging signature showed a significant correlation
(median ρ = 0.81, range = 0.80, 0.82), suggesting that this
approach does not bias the results.
4.6 | Searching the drug databases for CMap drugs
Entries in CMap are composed of the drug names, which are gener-
ally the catalogue names for the drugs from chemical vendors. Simi-
larly, DrugAge drugs also do not have an ID that is possible to map
across different databases. The DrugAge database was retrieved on
11th May 2017, from the DrugAge website. To compare the drugs
in CMap and the DrugAge, we first used the PubChem database
(Kim et al., 2016) to make a transition across different sources. We
obtained PubChem compound IDs for each drug in CMap and Dru-
gAge using PubChem API accessed through R programming environ-
ment and “RCurl” and “jsonlite” libraries.
4.7 | Targets of the drugs that are significantly
associated with aging
We compiled the drug–target associations for the drugs signifi-
cantly associated with aging mostly through literature research. For
the cases where the database entries are manually curated and
consistent, we used CHEMBL (Bento et al., 2014), DrugBank (Law
et al., 2014) and PubChem (Kim et al., 2016). We downloaded
GenAge model organism and human data sets (Tacutu et al., 2018)
on 10th October 2017 using GenAge website. Using the human
orthologues for the model organisms (genage_models_orthologs_ex-
port.tsv) and the human data set, we asked whether any of the
drug targets were previously shown to be implicated in aging. To
construct the drug–target network, we used “ggnetwork” package
in R.
4.8 | The prolongevity drug expression profile
To compile a set of gene expression changes that can be associated
with the known prolongevity drug profile, we first downloaded the
preprocessed data matrix with the drug‐induced expression changes
(“amplitudeMatrix.txt” from CMap FTP server ftp://ftp.broadinsti
tute.org/distribution/cmap). Using this matrix, for the seven
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prolongevity drugs in DrugAge that are among the significant associ-
ations according to our analysis, we generated a prolongevity drug
profile. We first identified the drug‐induced gene expression changes
for each of these seven drugs and each of the probe‐sets that are in
the microarray aging signature. For each drug–probe‐set pair, we
take the direction of change that is observed in at least 60% of the
experiments (using different doses or different cell lines) as the
effect of that drug on the expression of that probe‐set. After decid-
ing on the individual drug effects, we took the type of change
observed in at least four of seven drugs as the prolongevity drug
profile. The reason why we do not seek a perfect overlap among dif-
ferent drugs is to allow potentially different mechanism of actions to
be included in the prolongevity drug profile. As a result, we got five
categories: (a) increase in aging, increased by the drugs; (b) increase
in aging, decreased by the drugs; (c) decrease in aging, increased by
the drugs; (d) decrease in aging, decreased by the drugs; and (e) the
ones that are not affected consistently by the drugs. The full list of
genes in the first four categories is given as Supporting Information
Table S5. We also asked whether any of the GO Biological Pro-
cesses is enriched in any of the first four categories and thus did an
enrichment analysis. We calculated the odds ratio for each GO cate-
gory by keeping the type of change in aging the same. For example,
we asked whether a GO category is enriched in genes that increase
in aging and also increased by the drugs, compared to the genes that
increase in aging but decreased by the drugs. Because the number
of genes is small, it is not possible to detect significant associations
after correcting for multiple testing, and thus, we only report the
odds ratios for the categories (Supporting Information Table S6). We
also compared the known prolongevity drug profile we compiled
with the profile induced by the 24 drugs identified in the study (Sup-
porting Information Figure S9). We calculated the percentage of
probe‐sets that show the same type of change as the prolongevity
drug profile. For this, we again only considered probe‐sets that show
the same type of change in at least 60% of the experiments per
drug.
4.9 | Gene‐set enrichment analysis for drug‐induced
changes
Using the “amplitudeMatrix.txt” downloaded from the CMap web-
site, we determined the expression changes at the gene level for
each drug. We first subset the matrix to include only the experi-
ments for the 24 significant drugs we found. We then mapped
the probe‐set ids (total number of probe‐sets = 22,283) to Entrez
gene ids using the Ensembl biomaRt package in R. We map
19,222 probe‐sets to genes, excluding examples where the same
probe‐set id maps to multiple genes (628 multigene probe‐set ids
in total). The genes with more than one probe‐set id are repre-
sented by taking the median expression change induced for the
probe‐sets (number of genes = 12,064). When the experiments for
each drug are treated separately, we noticed that the results were
confounded by cell line. Thus, we then summarized multiple
experiments for each drug by taking the median of the change
they induce. In this way, we trimmed the cell‐line‐specific effects.
Then the expression changes (for 12,064 genes) for each drug (24
drugs) are rank ordered. Using clusterProfiler package and “gse-
KEGG” and “gseGO” functions, we performed GSEA for the gene
expression changes induced by each drug separately. For the
KEGG pathway analysis, we only considered the pathways with at
least 50 genes (188 pathways), and for GO analysis, we only con-
sidered Biological Process categories with at least 50 and maxi-
mum of 200 genes (1589 categories).
4.10 | Comparing brain aging signature to other
tissues
We calculated the proportion of genes that show a change in the
same direction with the aging signature compiled using brain data.
The proportions are calculated for aging signatures compiled using
the array and GTEx brain data, separately. We also analysed upregu-
lated and downregulated genes separately to observe any differential
pattern. To calculate the significance of similarity or dissimilarity, we
performed 10,000 permutations as follows: (a) N number of genes,
where N is the number of genes in a particular group (array/GTEx
and up‐/downregulated), were selected randomly from a given GTEx
data set; (b) the proportion of changes in a given direction is calcu-
lated; and (c) using the distribution of these proportions, we asked
how many times we obtain a value as extreme as the proportion cal-
culated for that tissue and assign empirical p‐value.
4.11 | Side effects
Using compound PubChem IDs, we subset the Side Effect
Resource (SIDER 4.1; Kuhn, Letunic, Jensen, & Bork, 2016), a
database of adverse drugs reactions for marketed medicines. The
latest version of SIDER codes the side effects using the Medical
Dictionary for Regulatory Activities (MedDRA), an adverse event
classification dictionary. To obtain term at the system level, we
mapped the lowest level MedDRA terms in SIDER (LLT codes) to
MedDRA System Organ Class terms (SOC codes) using hierarchical
files downloadable from the MedDRA Web‐based browser
(https://tools.meddra.org/wbb/). A total of eight drugs among the
24 had labelled side effects.
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